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Recently, the American College of Cardiology (ACC) and the American Heart Association 
(AHA) issued new guidelines on management of cardiovascular (CV) risk in primary prevention.1 
They developed a new CV risk calculator (new pooled cohort atherosclerotic CV disease risk 
equation) targeting individuals between 40-75 years and based on 4 American population-based 
cohorts.2, 3 Statin treatment is recommended for individuals with an estimated 10-year risk of 
CV disease (CVD) ≥7.5%, including stroke. Conversely, the guidelines of the European Society of 
Cardiology (ESC) advocate the use of the SCORE equation for individuals aged between 40 and 
65 years, and initiation of a statin treatment is recommended if the estimated 10-year risk of 
death from CVD is ≥5%.4 Whether applying the ACC/AHA guidelines has similar public health 
consequences as applying the ESC guidelines is currently unknown. Hence, we used the data 
from a large, population-based study, to assess the countrywide population and economic 
impact of these new guidelines, supposing full adherence to treatment recommendations.  
Data from the Swiss CoLaus study, collected between 2003 and 2006 in 3,297 
participants (1,854 women) aged 50 to 75 years, was used.5 Ten-year CVD risk was computed 
according to the Swiss SCORE (ESC) and the 2013 ACC/AHA risk equations; results were 
extrapolated to the Swiss population of the same age group. The Swiss SCORE equation has 
been validated in individuals up to 75 years of age. Daily cost of treatment was estimated using 
one widely used statin, i.e. atorvastatin. 
The results are summarized in the table. Irrespective of the risk equation used, the 
prevalence of high-risk individuals increased considerably with age, exceeding 80% among 
participants aged over 70 years. Extrapolated to the Swiss population, applying the ACC/AHA 
guidelines more than doubled the prevalence of high-risk individuals (2.2-fold in men and 1.9 
fold in women) relative to the SCORE function. The biggest differences were observed for age 
group 50 to 60 years, where the ACC/AHA guidelines led to a 30-fold increase in the number of 
high-risk individuals relative to the ESC guidelines. Full compliance with the ACC/AHA guidelines 
would also lead to an extra cost of treatment of 1.124 million CHF per day (410 million CHF, or 
333.7 million €, per year). 
We conclude that, relative to the ESC guidelines, the 2013 ACC/AHA guidelines lead to a 
considerable increase in the number of high-risk individuals susceptible of receiving statin 
treatment. This increase is particularly strong in the age group 50-60 years. One likely 
explanation for this discrepancy may be due to differences in the prevalence of CV risk factors 
between the US and Europe.6, 7 Consequently, if fully implemented, the ACC/AHA guidelines 
might lead to a considerable increase in primary prevention costs of CVD. Further studies are 
needed to validate the new ACC/AHA risk equation and to assess the cost-effectiveness of the 
ACC/AHA guidelines in non-US countries. 
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Table : simulations of the population impact and of daily costs related to treatment with atorvastatin in Switzerland according to the European 
Society of Cardiology (ESC) or 2013 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines 
Swiss population Population at risk * 
Ratio ACC/AHA to ESC † Daily cost of 
treatment ‡ 
ESC Men Women Total Men Women Total Men Women Total Atorvastatin § 
[50-60[ 561'013 551'105 1'112'118 8'976 - || 8'976 - - - 13 
[60-70[ 429'528 448'861 878'389 204'026 29'176 233'202 - - - 350 
[70-75[ 176'448 205'307 381'755 175'389 181'491 356'881 - - - 536 
All 1'814'130 1'841'332 3'655'462 388'391 210'667 599'059 - - - 899 
ACC/AHA 
[50-60[ 561'013 551'105 1'112'118 274'335 23'698 298'033 30.6 NA 33.2 447 
[60-70[ 429'528 448'861 878'389 419'649 169'221 588'869 2.1 5.8 2.5 884 
[70-75[ 176'448 205'307 381'755 176'448 204'486 380'934 1.0 1.1 1.1 572 
All 1'166'989 1'205'273 2'372'262 870'432 397'405 1'267'836 2.2 1.9 2.1 2'023 
* according to the ACC/AHA (new pooled cohort atherosclerotic CV disease risk equation) or ESC guidelines (Swiss SCORE equation).
† ratio of the number of subjects at risk according to ACC/AHA guidelines to the number of subjects at risk according to ESC guidelines. NA: not 
assessable. 
‡ expressed in 1,000 CHF. To obtain €, multiply by 0.814; to obtain US$, multiply by 1.110. Currency exchange rates as of January 3rd 2014 were 
applied. 
§ fixed daily price independent of dosing (10-80 mg).
|| SCORE equation do not predict CV risk for women under 60 years. 
